Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Inhibitor Therapeutics, Inc. (INTI) had Return on Tangible Equity of 34.70% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-0.69M |
|
-- |
|
-- |
|
$0.70M |
|
$-0.70M |
|
$0.01M |
|
$-0.69M |
|
$-0.69M |
|
$-0.69M |
|
$-0.69M |
|
$-0.69M |
|
$-0.69M |
|
$-0.70M |
|
$-0.70M |
|
172.57M |
|
172.57M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$1.38M |
|
-- |
|
$0.06M |
|
$1.43M |
|
$0.38M |
|
-- |
|
$3.03M |
|
$3.41M |
|
$-1.98M |
|
$-1.98M |
|
$-1.98M |
|
172.57M |
|
| Cash Flow Statement Financials | |
$-1.08M |
|
-- |
|
-- |
|
$2.38M |
|
$1.29M |
|
$-1.08M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.60 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.08M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
34.70% |
|
|
Return on Tangible Equity |
34.70% |
-47.89% |
|
34.70% |
|
$-0.01 |
|
$-0.01 |
|
$-0.01 |
|